January 31st, 2014
John Ryan offers a primer on three newly approved drugs for pulmonary arterial hypertension.
March 25th, 2013
For the second time the FDA has issued a complete response letter rejecting the new drug application (NDA) of oral treprostinil for the treatment of pulmonary arterial hypertension (PAH). The manufacturer of the drug, United Therapeutics, said in a press release that it planned to discuss the decision with the FDA. “We remain confident that oral treprostinil will play […]